These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 19270631)

  • 1. Antipsychotics side effects' influence on stigma of mental illness: focus group study results.
    Novak L; Svab V
    Psychiatr Danub; 2009 Mar; 21(1):99-102. PubMed ID: 19270631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stigmatizing experience and structural discrimination associated with the treatment of schizophrenia in Hong Kong.
    Lee S; Chiu MY; Tsang A; Chui H; Kleinman A
    Soc Sci Med; 2006 Apr; 62(7):1685-96. PubMed ID: 16174547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is antipsychotic medication stigmatizing for people with mental illness?
    Sajatovic M; Jenkins JH
    Int Rev Psychiatry; 2007 Apr; 19(2):107-12. PubMed ID: 17464788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Discrimination perceived by people with a diagnosis of schizophrenic disorders. INternational study of DIscrimination and stiGma Outcomes (INDIGO): French results].
    Daumerie N; Vasseur Bacle S; Giordana JY; Bourdais Mannone C; Caria A; Roelandt JL
    Encephale; 2012 Jun; 38(3):224-31. PubMed ID: 22726410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stigmatization in the long-term treatment of psychotic disorders.
    Oral ET
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():35-45. PubMed ID: 17262008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Awareness of stigma among persons with schizophrenia: marking the contexts of lived experience.
    Jenkins JH; Carpenter-Song EA
    J Nerv Ment Dis; 2009 Jul; 197(7):520-9. PubMed ID: 19597360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosocial and socio-demographic correlates of medication compliance among people with schizophrenia.
    Tsang HW; Fung KM; Corrigan PW
    J Behav Ther Exp Psychiatry; 2009 Mar; 40(1):3-14. PubMed ID: 18417098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness.
    Megna JL; Kunwar AR; Mahlotra K; Sauro MD; Devitt PJ; Rashid A
    J Psychiatr Pract; 2007 Mar; 13(2):129-37. PubMed ID: 17414692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What information do patients with schizophrenia have about their illness and treatment?].
    Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
    Encephale; 2000; 26(5):30-8. PubMed ID: 11192802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment adherence in schizophrenia and schizoaffective disorder.
    Goff DC; Hill M; Freudenreich O
    J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia.
    McCann TV; Clark E; Lu S
    J Adv Nurs; 2009 Mar; 65(3):534-43. PubMed ID: 19222651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stigma, social function and symptoms in schizophrenia and schizoaffective disorder: associations across 6 months.
    Lysaker PH; Davis LW; Warman DM; Strasburger A; Beattie N
    Psychiatry Res; 2007 Jan; 149(1-3):89-95. PubMed ID: 17156853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders.
    Chiang YL; Klainin-Yobas P; Ignacio J; Chng CM
    J Clin Nurs; 2011 Aug; 20(15-16):2172-82. PubMed ID: 21539628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
    Patel MX; De Zoysa N; Bernadt M; David A
    J Psychopharmacol; 2009 Sep; 23(7):789-96. PubMed ID: 18583438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.